Efficacy of Sphinkeeper™ implant in treating faecal incontinence

F. Litta¹, A. Parello¹, V. De Simone¹, P. Campennì¹, R. Orefice¹, A. A. Marra¹, M. Goglia¹, R. Moroni² and C. Ratto¹,³

¹Proctology Unit and ²Direzione Scientifica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, and ³Università Cattolica del Sacro Cuore, Rome, Italy (e-mail: carloratto@tiscali.it)

Correspondence to: Prof. C. Ratto, Proctology Unit, Fondazione Policlinico Universitario, Agostino Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy (e-mail: carloratto@tiscali.it)

Presented to the 14th Scientific and Annual Meeting of the European Society of Coloproctology, Vienna, Austria, September 2019, published in abstract form as Colorectal Dis 2019; 21: 116

© 2020 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.

Introduction

Faecal incontinence is a common condition, affecting up to 19.5 per cent of the general population, which has a negative effect on quality of life (QoL)³. Management of faecal incontinence can be challenging owing to its multifactorial aetiology. When conservative treatment fails (dietary modifications, pharmacological treatment and pelvic floor rehabilitation programmes), surgical intervention can be considered, but is limited by a lack of long-term improved continence²,³. Sacral nerve stimulation (SNS) has been popularized recently as it has been found to be of significant benefit in selected patients, but the risk of complications and time spent learning the operation are not insignificant⁴. The Gatekeeper™ (GK; THD SpA, Correggio, Italy) procedure, introduced to treat faecal incontinence in 2011⁵, involves implanting four or six self-expandable prostheses into the intersphincteric space of the anal canal when the sphincter is intact or there is only a small defect in the internal anal sphincter. The initial GK procedure was later modified to the Sphinkeeper™ (SK) procedure (THD SpA, Correggio, Italy) (Fig. 1), whereby ten modified prostheses (longer and larger than GK) are inserted into the intersphincteric space⁶. The SK allows treatment of more sizeable defects in the internal or external anal sphincter, and preliminary feasibility data for the SK procedure have been encouraging⁶.

The primary aim of this prospective study was to assess the efficacy of the SK in patients with faecal incontinence. Secondary endpoints were QoL evaluation, safety of implantation, and frequency of prosthesis displacement.

Methods

A single-centre prospective observational study of SK prostheses (Fig. 1) was conducted at University Hospital A. Gemelli, Rome, Italy. The study protocol was approved by the local ethics committee (protocol number 30984).

Inclusion and exclusion criteria

Included patients were aged between 18 and 85 years; had experienced faecal incontinence for at least 6 months; had failed conservative treatment; had faecal incontinence episodes more than once a week; had a sphincter defect affecting no more than 120° of the internal or external sphincter, or both; and were able to consent to participate and attend all scheduled follow-up visits. Exclusion criteria were: current diagnosis of cancer; rectal bleeding of unknown origin; chronic diarrhoea unresponsive to medical treatment; inflammatory bowel disease; acute anorectal sepsis; concomitant rectal prolapse; obstructive defaecation syndrome; neurological disease; coagulation disorder; previous rectal resection; and sphincter(s) defects of the internal or external anal sphincter, or both, of more than 120° of anal canal circumference.

Study design

SK implantation was performed as described previously⁶. Follow-up visits were scheduled at 3, 6 and 12 months, and annually thereafter. At each visit, implant position was evaluated by endoanal ultrasonography. A prosthesis was considered adequately placed when at least two-thirds of it were found within the target area (Fig. 2). Prosthesis placement was considered adequate when the...
The device includes both the delivery system and dispensers in which a single prosthesis is placed; the prostheses are made of polyacrylonitrile (Hyexpan™; THD SpA, Correggio, Italy). When in a dehydrated state, they are thin and solid cylinders; 48h after contact with body fluids, they change size, becoming shorter.

The majority of prostheses (at least 6 of 10) were found in the target area.

**Assessment of faecal incontinence**

Symptoms of faecal incontinence were evaluated by means of a daily diary of faecal incontinence episodes over 2 weeks, ability to defer defaecation (in minutes), need to wear pads and/or take constipating drugs, and validated Cleveland Clinic Fecal Incontinence Score (CCFIS)\(^7\) and Vaizey score\(^8\). QoL and health status were assessed using the

| Table 1 Baseline patient characteristics | No. of patients* |
|------------------------------------------|------------------|
| Age (years)†                            | 66·6(10·6)       |
| Sex ratio (F: M)                         | 36:6             |
| Duration of FI (years)†                  | 6·8(6·1)         |
| Episodes of FI (per week)†               |                  |
| Soiling                                  | 8·2(6·4)         |
| Gas                                      | 13·9(12·4)       |
| Liquid stools                            | 2·9(3·4)         |
| Solid stools                             | 2·0(2·1)         |
| CCFIS score†                             | 12·0(3·7)        |
| Vaizey score†                            | 14·6(4·4)        |
| 3D-EAUS features                         |                  |
| Sphincter lesion(s)                      | 14               |
| IAS                                      | 2                |
| EAS                                      | 9                |
| IAS + EAS                                | 3                |
| Sphincter atrophy without lesion         | 33               |
| Urinary incontinence                     | 23               |
| Previous pelvic radiotherapy             | 2                |
| Previous anorectal surgery               |                  |
| Sacral nerve stimulation                 | 4                |
| Haemorrhoidectomy                        | 1                |
| Rectocele repair                         | 1                |
| Correction of anorectal malformation     | 1                |
| Co-morbidities                           |                  |
| Endocrine disease                        | 6                |
| Gynaecological disease                   | 4                |
| Diabetes                                 | 3                |
| Neurological disease                     | 2                |

*With percentages in parentheses unless indicated otherwise; †values are mean(s.d.). FI, faecal incontinence; CCFIS, Cleveland Cleveland Clinic Fecal Incontinence Score; 3D-EAUS, three-dimensional endoanal ultrasonography; IAS, internal anal sphincter; EAS, external anal sphincter.
| Table 2 Number of soiling and incontinence episodes per week, and faecal incontinence severity scores at baseline and during follow-up |
|---------------------------------------------------------------|
|                                                                 |
| **Baseline** (n = 42)                                         | **3 months** (n = 42) | **6 months** (n = 42) | **12 months** (n = 28) | **Last follow-up** (n = 42) | **P*** |
| Soiling (episodes per week)                                   | 8.2(6-4)              | 5.2(4-7)              | 3.0(3-6)               | 3.1(3-8)                    | 3.2(3-8) | <0.001 |
| Incontinence to gas (episodes per week)                       | 13.9(12-4)            | 9.6(7-8)              | 7.1(6-7)               | 7.0(6-7)                    | 7.5(7-1)  | 0.001  |
| Incontinence to liquid stools (episodes per week)             | 2.9(3-4)              | 2.1(3-0)              | 1.1(1-6)               | 1.1(1-6)                    | 1.4(1-9)  | 0.005  |
| Incontinence to solid stools (episodes per week)              | 2.0(2-1)              | 1.3(1-5)              | 0.9(1-5)               | 0.6(1-4)                    | 0.8(1-5)  | 0.003  |
| CCFIS score                                                   | 12.0(3-7)             | 10.1(3-8)             | 7.8(4-1)               | 7.7(4-2)                    | 7.6(4-1)  | <0.001 |
| Vaizey score                                                  | 14.6(4-4)             | 13.0(4-7)             | 10.2(5-0)              | 10.0(4-5)                   | 10.2(4-7) | 0.001  |

Values are mean(s.d.). CCFIS, Cleveland Clinic Fecal Incontinence Score. *Comparison between baseline and data collected at last follow-up session (Wilcoxon test).

Faecal Incontinence Quality of Life Scale (FIQL)\(^9\) and Short Form 36 (SF-36\(^{®}\); Rand Corporation, Santa Monica, CA, USA) questionnaires\(^{10}\). Anorectal manometry and endoanal ultrasonography were used for both the assessment of anorectal function and morphology, and evaluation of the location of the SK prosthesis after implantation.

**Results**

Between March 2016 and October 2018, 45 consecutive patients (36 women; mean(s.d.) age 66.6(10.6), range 38–85 years) underwent SK implantation. Baseline clinical characteristics are summarized in **Table 1**. Three patients were lost to follow-up after the first postoperative visit, leaving 42 for evaluation. Mean follow-up was 15.9(8.6) (range 6–33) months. Single implant delivery failed in two patients, and was reattempted successfully during the same procedure. No patient sustained intraoperative or postoperative complications.

**Continence**

Compared with baseline values, faecal incontinence of all types decreased (**Table 2**). Five patients became fully continent. The number of patients who never or rarely experienced postdefaecation soiling episodes increased

![Fig. 3 Frequency of postdefaecation episodes of soiling at baseline and during follow-up](image-url)

*Data collected at last follow-up session. Frequency: never – none; rarely – less than once per month; sometimes – less than once per week to once or more per month; often – less than once per day to at least once per week; always – at least once per day. \(\dagger\) P < 0.001 versus baseline (marginal homogeneity test).
significantly from three at baseline to 23 at date of last follow-up ($P < 0.001$) (Fig. 3). The ability to defer defaecation improved significantly, with 14 patients able to defer for more than 5 min at baseline, compared with 29 at last follow-up ($P = 0.001$). The mean(s.d.) CCFIS changed from 12.0(3.7) at baseline to 7.6(4.1) at last follow-up ($P < 0.001$); similarly, the Faizey score decreased from 14.6(4.4) to 10.2(4.7) ($P < 0.001$).

**Quality of life, anorectal manometry and endoanal ultrasonography findings**

All domains of the FIQL improved after the SK procedure (Fig. S1, supporting information), but only physical functioning improved on the SF-36® questionnaire (Table S1, supporting information). Maximum squeeze pressure increased, from mean(s.d.) 80.7(68.5) mmHg at baseline to 90.1(48.7) mmHg at last follow-up ($P = 0.006$), with no difference in maximum resting pressure and rectal sensory thresholds. Full anorectal manometry results are available in Table S2 (supporting information).

At the last follow-up, endoanal ultrasound assessment of prosthesis position found that SK implantation was adequate in 23 of the 42 patients, with at least six of ten prostheses placed in the target area. Patients with adequate SK placement had improved outcomes and CCFIS compared with those with inadequate placement (Tables S3 and S4, supporting information).

**Patients with anal sphincter lesions**

Fourteen patients (all women; mean age 67.4(9.3) years) with faecal incontinence and anal sphincter defects underwent SK implantation. The range of sphincter defect extension was 30–120° for the internal anal sphincter and 30–120° for the external anal sphincter. After SK placement, eight of 14 patients showed an over 50 per cent reduction in the total number of faecal incontinence episodes per week (Table S5, supporting information).

**Discussion**

This study of 42 patients undergoing a SK procedure for faecal incontinence found improved incontinence in the majority of patients during the early postoperative phase and long-term follow-up, regardless of the type of faecal incontinence treated. The SK procedure used more prostheses than the previously described GK procedure. The prostheses are optimally positioned circumferentially at high–middle anal canal level, similar to a ‘third sphincter’ between the internal and external sphincters. This aims to reinforce and/or reshape the area where the continence mechanisms are elicited physiologically through the rectoanal inhibitory reflex. The observed improvement in soiling and gas continence is particularly relevant because these are challenging to control with other treatment modalities. It is accepted that any procedure to treat faecal incontinence is unlikely to result in perfect continence. In such situations, SK could be considered a helpful ‘adjuvant therapy’ following other treatment strategies.

The finding of no intraoperative or perioperative procedure morbidity in the present study is in keeping with previously published data on GK and SK procedures. Given that the procedure can be performed under local anaesthesia, it can be considered in elderly patients and those with co-morbidities. The finding of improved continence across different faecal incontinence aetiologies may be related to the bulking effect of the SK, with larger volumes of material implanted than with previous techniques, adding bulk between the internal and external sphincter which can increase muscle fibre length and therefore improve contractility. This may explain why an increase in squeeze but not resting pressures was seen on anorectal manometry. It may also explain why continence improved in patients with a 30–120° sphincter defect, and, for defects larger than 120°, why the SK can be used in combination with sphincter repair or SNS.

This study has some limitations, including a relatively small and heterogeneous sample size and the inclusion of patients with potentially more severe disease. The study also describes a single-centre experience and the results may not translate to other units. Future larger multicentre trials are required to confirm the efficacy and indications for the SK.

**Acknowledgements**

F.L. and C.R. contributed equally to this work. C.R. received travel reimbursement from THD to attend conferences.

**Disclosure:** The authors declare no other conflict of interest.

**References**

1. Sharma A, Yuan L, Marshall RJ, Merrie AE, Bissett IP. Systematic review of the prevalence of faecal incontinence. *Br J Surg* 2016; 103: 1589–1597.
2. Tjandra JJ, Chan MK, Yeh CH, Murray-Green C. Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: a randomized, controlled study. *Dis Colon Rectum* 2008; 5: 494–502.
3 Glasgow SC, Lowry AC. Long-term outcomes of anal sphincter repair for fecal incontinence: a systematic review. *Dis Colon Rectum* 2012; 55: 482–490.

4 Bielefeldt K. Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration. *World J Gastrointest Pharmacol Ther* 2016; 7: 294–305.

5 Ratto C, Parello A, Donisi L, Litta F, De Simone V, Spazzafumo L *et al.* Novel bulking agent for faecal incontinence. *Br J Surg* 2011; 98: 1644–1652.

6 Ratto C, Donisi L, Litta F, Campennì P, Parello A. Implantation of SphinKeeper™: a new artificial anal sphincter. *Tech Coloproctol* 2016; 20: 59–66.

7 Jorge JM, Wexner SD. Etiology and management of fecal incontinence. *Dis Colon Rectum* 1993; 36: 77–97.

8 Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal incontinence grading systems. *Gut* 1999; 44: 77–80.

9 Rockwood TH, Church JM, Fleshman JW, Kane RL, Mavrantonis C, Thorson AG *et al.* Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. *Dis Colon Rectum* 2000; 43: 9–16.

10 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. *Med Care* 1992; 30: 473–483.

11 Altomare DF, Giuratrabocchetta S, Knowles CH, Muñoz Duyos A, Robert-Yap J, Matzel KE; European SNS Outcome Study Group. Long-term outcomes of sacral nerve stimulation for faecal incontinence. *Br J Surg* 2015; 102: 407–415.

12 Ratto C, Buntzen S, Aigner F, Altomare DF, Heydari A, Donisi L *et al.* Multicentre observational study of the Gatekeeper™ for faecal incontinence. *Br J Surg* 2016; 103: 290–299.

13 Trenti L, Biondo S, Nogueiras F, Nomdedeu J, Coret A, Scherer R *et al.* Outcomes of Gatekeeper™ prosthesis implantation for the treatment of fecal incontinence: a multicenter observational study. *Tech Coloproctol* 2017; 21: 963–970.

14 de la Portilla F, Reyes-Díaz ML, Maestre MV, Jiménez-Rodríguez RM, García-Cabrera AM, Vázquez-Monchul JM *et al.* Ultrasonographic evidence of Gatekeeper™ prosthesis migration in patients treated for faecal incontinence: a case series. *Int J Colorectal Dis* 2017; 32: 437–440.

**Supporting information**

Additional supporting information can be found online in the Supporting Information section at the end of the article.

**Editor’s comments**

Faecal incontinence can be devastating, making life miserable. Many surgical options exist, but the problem is that none is particularly effective, especially with minimal risk. The authors herein report data on a new concept built upon previous technological solutions to bulk the anal sphincter complex. While previous attempts at this type of intervention were only minimally successful, the technology has evolved to contain an increased number of rods which further bulk the internal sphincter. The rate of complications reported is low, so even if only a modest success is found in larger numbers of patients, it may be an intervention worth trying.

A. Lightner

*Associate Editor, BJS*